Skip to main content

Table 2 Characteristics of patients enrolled in therapeutic trials following molecular profiling

From: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

  All trials Genotype-matched Genotype-unmatched p value
Median age (range) 58 (18–81) 58 (24–81) 58.5 (18–80) NS
Female/Male 205/72 64/25 141/47 NS
Median prior systemic therapies (range) 2 (1–16) 2 (1–11) 2 (1–16) NS
Tumor type (number of patients)
 Breast 47 22 25 NS
 Colorectal 43 18 25
 Lung 48 18 30
 Gynecological 91 22 69
 Other 48 9 39
Genotyping platform (number of patients)
 MALDI-TOF MS panel 176 61 115 NS
 TruSeq Amplicon cancer panel 101 28 73
 Ampliseq cancer panel 0 0 0
Trial phase (number of patients)
 Phase I 158 72 86 <0.001
 Phase II 67 9 58
 Phase III 52 8 44
Investigational agent(s) (number of patients)
 Targeted monotherapy 112 23 89 <0.001
 Targeted drug combination 87 59 28
 Targeted drug and chemotherapy 43 7 36
 Immunotherapy 34 0 34
 Radiotherapy 1 0 1
  1. NS not significant